Gyre Therapeutics Inc. (GYRE) - Net Assets
Based on the latest financial reports, Gyre Therapeutics Inc. (GYRE) has net assets worth $136.99 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($162.01 Million) and total liabilities ($25.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Gyre Therapeutics Inc. tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $136.99 Million |
| % of Total Assets | 84.55% |
| Annual Growth Rate | 4.45% |
| 5-Year Change | 246.28% |
| 10-Year Change | 785.33% |
| Growth Volatility | 171.43 |
Gyre Therapeutics Inc. - Net Assets Trend (2002–2025)
This chart illustrates how Gyre Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. See Gyre Therapeutics Inc. (GYRE) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Gyre Therapeutics Inc. (2002–2025)
The table below shows the annual net assets of Gyre Therapeutics Inc. from 2002 to 2025. For live valuation and market cap data, see Gyre Therapeutics Inc. market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $142.28 Million | +44.59% |
| 2024-12-31 | $98.40 Million | +605.44% |
| 2023-12-31 | $13.95 Million | -80.68% |
| 2022-12-31 | $72.22 Million | +75.76% |
| 2021-12-31 | $41.09 Million | -45.98% |
| 2020-12-31 | $76.07 Million | +11.32% |
| 2019-12-31 | $68.34 Million | -43.03% |
| 2018-12-31 | $119.94 Million | +289.76% |
| 2017-12-31 | $30.77 Million | +91.49% |
| 2016-12-31 | $16.07 Million | -48.86% |
| 2015-12-31 | $31.43 Million | -71.19% |
| 2014-12-31 | $109.08 Million | -18.96% |
| 2013-12-31 | $134.61 Million | -23.48% |
| 2012-12-31 | $175.91 Million | +0.93% |
| 2011-12-31 | $174.29 Million | +89.76% |
| 2010-12-31 | $91.85 Million | +33.13% |
| 2009-12-31 | $68.99 Million | +20.25% |
| 2008-12-31 | $57.37 Million | +11.22% |
| 2007-12-31 | $51.58 Million | -20.64% |
| 2006-12-31 | $65.00 Million | +140.00% |
| 2005-12-31 | $-162.48 Million | -32.14% |
| 2004-12-31 | $-122.97 Million | -367.74% |
| 2003-12-31 | $45.93 Million | -12.17% |
| 2002-12-31 | $52.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gyre Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2973500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $91.00 | 0.00% |
| Other Comprehensive Income | $2.32 Million | 2.19% |
| Other Components | $172.14 Million | 162.35% |
| Total Equity | $106.03 Million | 100.00% |
Gyre Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Gyre Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai Sanyou Medical Co Ltd
SHG:688085
|
$589.94 Million |
|
SmartFinancial, Inc.
NASDAQ:SMBK
|
$590.02 Million |
|
Dexus Convenience Retail REIT
AU:DXC
|
$590.26 Million |
|
Yes Optoelectronics Co Ltd Class A
SHE:002952
|
$590.38 Million |
|
HelloFresh SE
XETRA:HFG
|
$589.85 Million |
|
Chularat Hospital Public Company Limited
BK:CHG-R
|
$589.72 Million |
|
PRINC.PR.EQ.HLDGS EO-001
F:PEYA
|
$589.52 Million |
|
Musti Group Oyj
HE:MUSTI
|
$589.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gyre Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 63,319,000 to 106,031,000, a change of 42,712,000 (67.5%).
- Net income of 5,027,000 contributed positively to equity growth.
- New share issuances of 23,509,000 increased equity.
- Other comprehensive income increased equity by 1,818,000.
- Other factors increased equity by 12,358,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $5.03 Million | +4.74% |
| Share Issuances | $23.51 Million | +22.17% |
| Other Comprehensive Income | $1.82 Million | +1.71% |
| Other Changes | $12.36 Million | +11.66% |
| Total Change | $- | 67.46% |
Book Value vs Market Value Analysis
This analysis compares Gyre Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.92x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | $-14701.50 | $6.08 | x |
| 2002-12-31 | $-24331.54 | $6.08 | x |
| 2003-12-31 | $-38718.98 | $6.08 | x |
| 2004-12-31 | $-58919.92 | $6.08 | x |
| 2005-12-31 | $-65122.69 | $6.08 | x |
| 2006-12-31 | $501.99 | $6.08 | x |
| 2007-12-31 | $274.65 | $6.08 | x |
| 2008-12-31 | $244.25 | $6.08 | x |
| 2009-12-31 | $282.57 | $6.08 | x |
| 2010-12-31 | $319.86 | $6.08 | x |
| 2011-12-31 | $578.44 | $6.08 | x |
| 2012-12-31 | $551.76 | $6.08 | x |
| 2013-12-31 | $420.15 | $6.08 | x |
| 2014-12-31 | $339.07 | $6.08 | x |
| 2015-12-31 | $106.43 | $6.08 | x |
| 2016-12-31 | $20.64 | $6.08 | x |
| 2017-12-31 | $8.99 | $6.08 | x |
| 2018-12-31 | $10.70 | $6.08 | x |
| 2019-12-31 | $5.69 | $6.08 | x |
| 2020-12-31 | $3.97 | $6.08 | x |
| 2021-12-31 | $1.34 | $6.08 | x |
| 2022-12-31 | $0.56 | $6.08 | x |
| 2023-12-31 | $-0.24 | $6.08 | x |
| 2024-12-31 | $0.62 | $6.08 | x |
| 2025-12-31 | $1.03 | $6.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gyre Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.31%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 1.57x
- Recent ROE (4.74%) is above the historical average (-32.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 0.00% | -428.77% | 0.07x | 0.00x | $-3.48 Million |
| 2002 | 0.00% | -921.78% | 0.04x | 0.00x | $-14.74 Million |
| 2003 | 0.00% | -789.06% | 0.05x | 0.00x | $-10.32 Million |
| 2004 | 0.00% | -642.67% | 0.06x | 0.00x | $-11.73 Million |
| 2005 | 0.00% | -2457.08% | 0.04x | 0.00x | $-12.74 Million |
| 2006 | 3.23% | 7.61% | 0.34x | 1.25x | $-4.40 Million |
| 2007 | -54.42% | -242.51% | 0.12x | 1.92x | $-33.23 Million |
| 2008 | -44.73% | -127.76% | 0.20x | 1.72x | $-31.40 Million |
| 2009 | -57.11% | -157.23% | 0.08x | 4.63x | $-46.30 Million |
| 2010 | 11.87% | 12.72% | 0.33x | 2.86x | $1.71 Million |
| 2011 | -4.89% | -8.74% | 0.38x | 1.48x | $-25.96 Million |
| 2012 | -3.98% | -12.09% | 0.31x | 1.08x | $-24.59 Million |
| 2013 | -34.70% | -1286.99% | 0.02x | 1.08x | $-60.17 Million |
| 2014 | -29.91% | -11862.91% | 0.00x | 1.03x | $-43.53 Million |
| 2015 | -46.98% | -843.54% | 0.03x | 2.21x | $-17.90 Million |
| 2016 | -105.44% | -4246.87% | 0.01x | 2.37x | $-18.55 Million |
| 2017 | -70.06% | -2117.98% | 0.03x | 1.28x | $-24.64 Million |
| 2018 | -25.06% | -500916.67% | 0.00x | 1.04x | $-42.05 Million |
| 2019 | -80.75% | 0.00% | 0.00x | 1.44x | $-62.01 Million |
| 2020 | -73.02% | -265.14% | 0.22x | 1.25x | $-63.15 Million |
| 2021 | -214.01% | -1198.32% | 0.13x | 1.35x | $-92.04 Million |
| 2022 | 5.41% | 2.25% | 1.21x | 1.99x | $-1.95 Million |
| 2023 | 0.00% | -81.92% | 0.97x | 0.00x | $-91.35 Million |
| 2024 | 19.09% | 11.43% | 0.84x | 1.98x | $5.75 Million |
| 2025 | 4.74% | 4.31% | 0.70x | 1.57x | $-5.58 Million |
Industry Comparison
This section compares Gyre Therapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gyre Therapeutics Inc. (GYRE) | $136.99 Million | 0.00% | 0.18x | $589.93 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Gyre Therapeutics Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in th… Read more